# A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

Source: https://onco.cc/trials/nct07602777/  
OnCo record `nct07602777` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ris-Rez in sarcomas, run by GlaxoSmithKline, now recruiting.

## Summary

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) is a phase 1/2 interventional study registered as NCT07602777 by GlaxoSmithKline, with 113 participants planned, started 2026-06-22 and due to reach its primary completion in 2027-11-18. Interventions recorded: Ris-Rez and G-CSF.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07602777
- Phase: 1/2
- Setting: Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas
- Sponsor: GlaxoSmithKline
- Enrolled: 113

## Sources

- ClinicalTrials.gov NCT07602777: https://clinicaltrials.gov/study/NCT07602777

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct07602777.json